Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology
April 29 2013 - 5:00AM
Business Wire
At the 23rd European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID), Bruker shows new capabilities of the
MALDI Biotyper™ platform.
"Professor David Livermore, University of
East Anglia, Norwich, UK" (Photo: Business Wire)
The MALDI Biotyper (MBT) is the market-leading system for
microbial identification based on MALDI-TOF mass spectrometry. It
is widely used in clinical microbiology, industrial microbiology,
animal health and food safety and has become the broadly accepted
laboratory standard for next generation microbial identification.
While conventional biochemical testing takes time-consuming
incubation after selection of the microbes from the culture plate,
the MALDI Biotyper allows for an instantaneous identification of
colonies from a plate. The MALDI Biotyper system covers a broad
range of more than 4,600 microbial isolates from gram-negative
bacteria, gram-positive bacteria, yeasts, multicellular fungi and
mycobacteria. It is broadly applicable as a standard identification
tool in various fields of microbiology. Microbial identification
with the MALDI Biotyper is done using a proteomic fingerprint. This
unique species-specific pattern is automatically compared with
reference spectra in the MALDI Biotyper library. In addition, the
MALDI Biotyper supports the Open Microbiology Concept which allows
customers to generate their own database entries from regional
isolates via a push-button storage in a customer-specific
sub-library.
The new second edition of the MBT Mycobacteria Library
adds another 140 isolates from 37 new species. The library is fully
compatible with all standard cultivation media for mycobacteria,
such as solid L�wenstein-Jensen medium or in liquid culture using
the MGIT™ system from Becton Dickinson. With these added
capabilities the MALDI Biotyper covers now more than 130 species of
mycobacteria.
The new MALDI Biotyper Pilot™ accessory complements the
satellite software to a complete, barcoded and paperless workflow.
The MBT Pilot is used for light-guided manual target
preparation using cross hairs to indicate the next position for
preparation on the MALDI target. Barcoding of the MALDI target and
the sample, along with multiple isolate support, ensure that the
complete process is fully traceable.
The new MALDI Biotyper Galaxy™ performs a
quality-controlled automated deposition of the MALDI matrix onto
the target plate. After the preparation it scans the target
positions and checks if each spot is optimally prepared for MALDI
Biotyper measurements. The MBT Galaxy has a seamless
integration into the MBT server coupled with on-board barcode
reading and automated loading of the associated project work list.
Both MBT Pilot and MBT Galaxy are scheduled to be
commercially available in 2013.
The revolutionary MALDI-Biotyper-Spectrum-Beta-Lactamase™
workflow (MSBL™) enables users to perform patented
functional beta-lactam antibiotic resistance testing for selected
antibiotics on the MALDI Biotyper platform. The cleavage of
beta-lactam antibiotics, like penicillins, 3rd generation
cephalosporins or carbapenems by resistant bacteria leads to
specific mass shifts of the cleaved products. Such mass shifts can
be observed and monitored using the MALDI Biotyper, and
automatically interpreted with the MSBL software module,
which is also expected to be commercially availability later this
year.
Dr. Wolfgang Pusch, Executive Vice President - Microbiology
Business at Bruker Daltonics, explained: “At the 2013 ECCMID in
Berlin, Bruker is again showcasing very significant developments to
further improve and streamline the established MALDI Biotyper
workflow. The MALDI Biotyper Pilot and MALDI Biotyper Galaxy
automation accessories add further functionality for quality
control and traceability and at the same time reduce the manual
workload of the operators. The MSBL method is another major
step ahead to apply the MALDI Biotyper platform also in the fields
of hospital hygiene and epidemiology to get fast results concerning
resistance of bacteria to selected antibiotics.”
Professor David Livermore, University of East Anglia, Norwich,
UK, commented: “I am very excited about the potential to detect
beta-lactamases - and maybe other resistances - as well as to
identify microbes by MALDI-TOF mass spectrometry. Early information
about resistance is very important to antibiotic stewardship.”
About the Bruker MALDI BiotyperThe dedicated MALDI
Biotyper solution enables molecular identification, and taxonomical
classification or dereplication of microorganisms like bacteria,
yeasts and fungi. Classification and identification of
microorganisms is achieved reliably and quickly using proteomic
fingerprinting by high-throughput MALDI-TOF mass spectrometry.
Applications include clinical routine microbial identification,
environmental and pharmaceutical analysis, taxonomical research,
food and consumer product safety and quality control, as well as
marine microbiology. The robust MALDI Biotyper method requires
minimal sample preparation and offers low consumables cost. The
MALDI Biotyper is available in a research-use-only version, or in
an IVD-CE version according to EU directive EC/98/79 in various
European countries. In the United States of America the MALDI
Biotyper is available for research use only, and not for use in
diagnostic procedures.
ABOUT BRUKER CORPORATION (NASDAQ: BRKR)Bruker is a
leading provider of high-performance scientific instruments and
solutions for molecular and materials research, as well as for
industrial, diagnostics and applied analysis. For more information:
www.bruker.com
*MGIT is a trademark of Becton Dickinson.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130429005006/en/
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024